Skip to main content

Table 5 Disease- or treatment related concomitant medication as reported by physicians

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

Cycle N Analgesics n (%) Antiemetics n (%) Antidiarrheals n (%) Dexa or similar steroids n (%) CSF n (%) Other medications n (%) RBC transfusions n (%) Platelet transfusions n (%)
Overall 521 387 (74.3) 435 (83.5) 66 (12.7) 496 (95.2) 58 (11.1) 292 (56.0) 126 (24.2) 18 ( 3.5)
Baseline 521 270 (51.8) 182 (34.9) 6 ( 1.2) 244 (46.8) 12 ( 2.3) 187 (35.9) 48 ( 9.2) 5 ( 1.0)
Cycle 1 516 265 (51.4) 270 (52.3) 7 ( 1.4) 452 (87.6) 5 ( 1.0) 196 (38.0) 20 ( 3.9) 2 ( 0.4)
Cycle 2 471 242 (51.4) 288 (61.1) 20 ( 4.2) 430 (91.3) 14 ( 3.0) 201 (42.7) 26 ( 5.5) 0 ( 0.0)
Cycle 3 421 226 (53.7) 260 (61.8) 16 ( 3.8) 391 (92.9) 14 ( 3.3) 186 (44.2) 29 ( 6.9) 4 ( 1.0)
Cycle 4 344 178 (51.7) 215 (62.5) 15 ( 4.4) 327 (95.1) 17 ( 4.9) 155 (45.1) 30 ( 8.7) 3 ( 0.9)
Cycle 5 278 142 (51.1) 179 (64.4) 8 ( 2.9) 268 (96.4) 11 ( 4.0) 137 (49.3) 14 ( 5.0) 1 ( 0.4)
Cycle 6 254 129 (50.8) 168 (66.1) 7 ( 2.8) 244 (96.1) 9 ( 3.5) 125 (49.2) 15 ( 5.9) 0 ( 0.0)
Cycle 7 150 93 (62.0) 87 (58.0) 4 ( 2.7) 143 (95.3) 4 ( 2.7) 96 (64.0) 7 ( 4.7) 0 ( 0.0)
Cycle 8 135 88 (65.2) 64 (47.4) 5 ( 3.7) 131 (97.0) 4 ( 3.0) 87 (64.4) 6 ( 4.4) 1 ( 0.7)
Cycle 9 110 75 (68.2) 52 (47.3) 2 ( 1.8) 105 (95.5) 1 ( 0.9) 77 (70.0) 4 ( 3.6) 0 (0.0)
Final 516 289 (56.0) 253 (49.0) 21 ( 4.1) 317 (61.4) 25 ( 4.8) 203 (39.3) 60 (11.6) 8 ( 1.6)
  1. CSF colony stimulating factors, Dexa dexamethasone, N = number of patients per cycle, RBC red blood cells
\